METAP1 Polyclonal antibody

METAP1 (methionyl aminopeptidase 1), also known as MAP1A or MetAP1A, is expected to be located in cytosol and widely expressed in esophagus and testis. The calculated molecular weight of METAP1 is 43 kDa. METAP1 is expected to have aminopeptidase activity and metallo-exopeptidase activity. It is also involved in platelet aggregation. At the same time, HsMetAP1 participates in co-translation to remove N- terminal methionine from newborn protein. Studies have shown that when HsMetAP1 is knocked down by gene-specific siRNA, cells show slow progress in G(2)/M phase, which is similar to cells treated with MetAP1 inhibitors. Importantly, MetAP1 inhibitors can induce apoptosis of leukemia cell lines, which may be the result of their interference with G(2)/M checkpoint. Therefore, it is necessary for normal cell cycle, especially in G(2)/M phase of cell cycle, and it can be used as a promising target for discovering and developing new anticancer drugs (PMID: 17114291).